University Hospital of Würzburg
Welcome,         Profile    Billing    Logout  
 18 Trials 
72 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
hassan, mohamed
NCT06545110: Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib

Active, not recruiting
1
120
RoW
Baricitinib Oral Tablet
South Valley University
Alopecia Areata
09/24
10/24
NCT04684953: Thyroid Autotransplantation in Quadriceps Femoris Muscle

Not yet recruiting
N/A
40
NA
Throid autotransplantation, Hormone
Assiut University
Thyroid
10/22
12/22
NCT05706428: Cardiorespiratory Effects of Nasal High Frequency Ventilation in Neonates

Completed
N/A
100
RoW
NHFOV, NCPAP
Alexandria University
Ventilator Lung; Newborn, Hemodynamic Instability, Echocardiography
09/23
10/23
NCT05814744: Efficacy of Adding Dexmedetomidine in Ultrasound-guided Intermediate Cervical Plexus Block for Thyroidectomy Surgery

Completed
N/A
60
RoW
dexmedetomidine, precedex vial, bupivacaine 0.25%, Sensorcaine®, Thyroidectomy Surgery, Ultrasound-guided intermediate Cervical Plexus Block Technique
National Cancer Institute, Egypt
Pain, Postoperative, Cancer of Larynx
10/23
11/23
NCT05884957: Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction

Completed
N/A
40
RoW
Nitric oxide synthase gene
Egymedicalpedia
Erectile Dysfunction, Diabetes Mellitus
12/23
01/24
NCT04804748: The DefiPace Study

Recruiting
N/A
450
Europe
No intervention
Institut für Pharmakologie und Präventive Medizin, Osypka AG
Post-operative Atrial Fibrillation POAF
01/26
08/26
NCT06412406: Comparison Between External Oblique Intercostal Plane Block and the Transversus Abdominis Plane Block in Paraumbilical Hernia Repair as Analgesia for Intraoperative and Postoperative Pain.

Not yet recruiting
N/A
62
NA
External Oblique Intercostal (EOI) block, Transversus abdominis plane (TAP) block
Assiut University
Paraumbilical Hernia
10/26
12/26
NCT05815771: Clinical and Magnetic Resonance Imaging Evaluation of Micro Fragmented Adipose Tissue Injection Combined With Bone Marrow Stem Cells on Healing of Temporomandibular Joint Internal Disc Derangement Without Reduction

Not yet recruiting
N/A
24
RoW
Micro fragmented adipose tissue mixed with bone marrow stem cells, Bone Marrow stem cells aspirate
Mohamed Talaat Abbas Hassan
Temporomandibular Joint Disorders
12/24
07/25
NCT06761820: Effect the Glycemic Control on Cardiac Function

Not yet recruiting
N/A
200
NA
Echocardiogram
Assiut University
Cardiac Function, Glycemic Control
09/26
12/26
NCT05106049: Serum Adiponectin as an Early Marker for Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease.

Not yet recruiting
N/A
90
NA
serum Adiponectin
Assiut University
Non-Alcoholic Fatty Liver Disease
12/22
01/23
NCT05605717: Liver Fibrosis and Steatosis in dm Non Invasive Evaluation

Not yet recruiting
N/A
60
RoW
Fibroscan, Abdominal ultrasound
Assiut University
Liver Diseases
09/23
09/23
NCT05556135: Role Of Serum Adiponectin In The Ealy Detection Of Renal Impairment In Patients With Non Alcoholic Fatty Liver Disease

Not yet recruiting
N/A
90
NA
level of serun adiponectin
Assiut University
Renal Impairment
10/23
10/23
Nordbeck, Peter
NCT04840667 / 2018-004689-32: A Study of Replagal in Treatment-naïve Adults With Fabry Disease

Terminated
3
17
Europe, Canada
REPLAGAL, SHP675
Shire
Fabry Disease
12/22
12/22
STAAR, NCT04046224 / 2019-000667-24: Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease

Active, not recruiting
1/2
34
Europe, Canada, US, RoW
ST-920
Sangamo Therapeutics
Fabry Disease
04/25
09/25
AIM-ICD, NCT04264455: Evaluation of Long-term Incidence of Ventricular Arrhythmias in Patients With Acute Myocarditis

Recruiting
N/A
34
Europe
Biomonitor, Life Vest, Implantable Cardioverter-Defibrillator (ICD)
Wuerzburg University Hospital, MVZ Leopoldina GmbH, Brandenburg Medical School Theodor Fontane, Hannover Medical School
Myocarditis Acute, Ventricular Arrythmia
12/22
12/23
NCT03022851: The Prophet Trial -Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Patients With Pulmonary Hypertension

Recruiting
N/A
30
Europe, RoW
Occlutech AFR Device
Occlutech International AB
Pulmonary Hypertension
02/23
12/23
DanShock, NCT01633502: Danish Cardiogenic Shock Trial

Completed
N/A
360
Europe
Conventional circulatory support, Conventional circulatory support will be employed according to enrolling sites usual management., Impella CP, Impella CP, Abiomed
Odense University Hospital, Aarhus University Hospital Skejby, Hannover Medical School, University Hospital, Bonn, Jena University Hospital, University Hospital Dresden, Heinrich-Heine University, Duesseldorf, Universitätsklinikum Hamburg-Eppendorf, Charite University, Berlin, Germany, Royal Brompton & Harefield NHS Foundation Trust, Wuerzburg University Hospital, Rigshospitalet, Denmark
Cardiogenic Shock Acute, Acute Myocardial Infarction
07/23
04/24
REDEAL-HF, NCT03966729: Relationships and Differences Analysis in Heart Failure

Recruiting
N/A
3000
Europe
Time (outcome)
Wuerzburg University Hospital
Heart Failure, Chronic Heart Failure, Chronic Heart Disease
12/23
12/23
MALTA-FABRY, NCT03683966: MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study

Recruiting
N/A
30
Europe
Wuerzburg University Hospital, Charite University, Berlin, Germany, University Hospital Muenster, Health Care Center Dr. Markus Cybulla, Muellheim
Rare Diseases, Fabry Disease, Adherence, Medication, Quality of Life
12/23
12/23
NCT05425459: RESPONDER-HF Trial

Recruiting
N/A
750
Europe, Canada, US, RoW
Corvia Atrial Shunt System / IASD System II, Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
Corvia Medical
Heart Failure, Heart Failure, Diastolic
05/25
03/31
PRAETORIAN-DFT, NCT03495297: A Randomised Trial of S-ICD Implantation with and Without Defibrillation Testing

Active, not recruiting
N/A
965
Europe, US
ommitence of defibrillation testing
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Boston Scientific Corporation
Ventricular Arrythmia
04/25
07/25
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Recruiting
N/A
1252
Europe, Canada, US
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Abiomed Inc.
Left Ventricular Dysfunction, Coronary Artery Disease
03/26
10/27
GoPEG, NCT06095713: German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa

Recruiting
N/A
60
Europe
Pegunigalsidase-alfa
Westfälische Wilhelms-Universität Münster, Chiesi GmbH
Fabry Disease
03/26
03/26
HEAL-FABRY, NCT03362164: Evaluation of HEArt invoLvement in Patients With FABRY Disease

Recruiting
N/A
650
Europe
Wuerzburg University Hospital, Competence Network Heart Failure, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), St George's, University of London
Rare Diseases, Fabry Disease, Fabry Disease, Cardiac Variant, Hypertrophic Cardiomyopathy
03/32
03/32
Liles, Darla
ATHN 16, NCT04647227: SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Recruiting
4
55
US
coagulation factor VIIa [recombinant]-jncw, SEVENFACT
American Thrombosis and Hemostasis Network, LFB USA, Inc.
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
09/26
03/27
NCT04657822 / 2020-004225-22: Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

Recruiting
4
130
Europe, US, RoW
Crizanlizumab, SEG101
Novartis Pharmaceuticals
Sickle Cell Disease
10/31
10/31
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
XPORT-MM-031, NCT05028348 / 2021-001691-41: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Hourglass Jul 2024 - Dec 2024 : H2'24 - Market entry in Malaysia in combination with bortezomib and dexamethasone for r/r MM
Jul 2024 - Dec 2024: Top-line data from XPORT-MM-031 trial in combination with pomalidomide and dexamethasone for multiple myeloma
Recruiting
3
222
Europe, US
Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral
Stichting European Myeloma Network, Karyopharm Therapeutics Inc
Multiple Myeloma
03/26
03/29
EQUATE, NCT04566328: Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the Trial

Recruiting
3
1450
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Daratumumab and Hyaluronidase-fihj, DARA Co-formulated with rHuPH20, DARA/rHuPH20, Daratumumab + rHuPH20, Daratumumab with rHuPH20, Daratumumab-rHuPH20, Daratumumab/Hyaluronidase-fihj, Daratumumab/rHuPH20 Co-formulation, Darzalex Faspro, Darzalex/rHuPH20, HuMax-CD38-rHuPH20, Recombinant Human Hyaluronidase Mixed with Daratumumab, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Quality-of-Life Assessment, Quality of Life Assessment
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
12/27
12/27
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
DETER-SMM, NCT03937635: Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Recruiting
3
288
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Smoldering Plasma Cell Myeloma
12/29
12/29
VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
2b
102
Europe, Canada, US, RoW
DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan
ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
10/24
04/25
SPARTAN, NCT03938454: A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

Completed
2
36
US
crizanlizumab, SEG101
Novartis Pharmaceuticals
Priapism
03/23
11/23
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
NCT05714969 / 2022-001940-36: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Active, not recruiting
2
40
Europe, US, RoW
TAK-755, rADAMTS13, recombinant ADAMTS13, SHP-655, BAX 930
Takeda, Takeda Development Center Americas, Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
03/25
03/25
PRESent-3, NCT05789537: A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

Active, not recruiting
2
3
Europe, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia B with Inhibitor, Hemophilia B
11/24
02/25
SURPASS-3, NCT05601752 / 2022-003176-16: ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer

Active, not recruiting
2
66
Europe, Canada, US
Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
Adaptimmune, GOG Foundation
Ovarian Cancer
08/26
08/26
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Active, not recruiting
2
60
Europe, Canada, US, RoW
SerpinPC, Activated Protein C (APC) inhibitor
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B
11/24
02/25
NCT05261711: AB1 in Adult Patients with Sickle Cell Disease (SCD)

Terminated
1/2
16
US
AB1
Nirmish Shah
Sickle Cell Disease
10/24
10/24
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

Active, not recruiting
1/2
122
Europe, US, RoW
Vodobatinib (K0706) capsules
Sun Pharma Advanced Research Company Limited
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
08/26
08/26
NCT06291415: The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

Recruiting
1
48
Europe, US, RoW
HMPL-523, sovleplenib
Hutchmed
Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases, Purpura, Thrombocytopenic, Purpura, Blood Coagulation Disorder, Thrombotic Microangiopathies, Hemorrhagic Disorders, Autoimmune Diseases, Immune System Diseases, Hemorrhage, Pathologic Processes, Skin Manifestations, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, Primary Immune Thrombocytopenia, ITP - Immune Thrombocytopenia
04/26
11/26
2018-523-00US1, NCT03779113: An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

Active, not recruiting
1
140
Europe, US
HMPL-523
Hutchmed
Non Hodgkin Lymphoma
12/24
01/26
NCT05660265: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

Recruiting
1
40
US
GSK4172239D, Placebo
GlaxoSmithKline
Hematologic Diseases, Anaemia, Sickle Cell
10/25
10/25
ONO-7018-01, NCT05515406: A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

Recruiting
1
108
US
ONO-7018
Ono Pharmaceutical Co. Ltd
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
12/27
12/27
NCT03994627: Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Approved for marketing
N/A
Europe, Canada, US, RoW
Olaratumab, LY3012207
Eli Lilly and Company
Soft Tissue Sarcoma
 
 
PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention

Terminated
N/A
108
Europe, Canada, US, RoW
No Intervention
ApcinteX Ltd, Centessa Pharmaceuticals plc
Hemophilia a, Hemophilia B
11/24
11/24
NCT04314401: National Cancer Institute "Cancer Moonshot Biobank"

Recruiting
N/A
1000
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Medical Chart Review, Chart Review
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Multiple Myeloma, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
09/25
09/25
INSIGHT, NCT03289780: Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects

Active, not recruiting
N/A
5006
US
Biodesix, Inc.
Non-Small Cell Lung Cancer
12/25
12/25
realMIND, NCT04981795: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Recruiting
N/A
100
US
Tafasitamab
Incyte Corporation, Iqvia Pty Ltd
Diffuse Large B-cell Lymphoma
10/25
08/26
PROSPECT, NCT04930445: Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD

Terminated
N/A
262
US
Oxbryta® (voxelotor) 500mg Tablets, Voxelotor, Oxbryta®
Pfizer, Pfizer
Sickle Cell Disease
10/24
10/24
Kraus, Sabrina
IDUNN, NCT04629833 / 2019-001462-15: Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy

Recruiting
3
210
Europe
MC0518, BAT
medac GmbH
Steroid-refractory Acute Graft-versus-host Disease
08/27
08/30
TRACE, NCT04832607 / 2018-000853-29: Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

Recruiting
3
149
Europe
Multivirus (CMV, EBV, AdV)-specific T cells
Prof. Tobias Feuchtinger, European Commission, Simbec-Orion Group Ltd, Merthyr Tydfil, UK, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany, Leiden University Medical Center, LUMC, Leiden, The Netherlands, Centre Hospitalier Universitaire de Nancy, CHU, Vandoeuvre-Lès-Nancy, France, Ghent University Hospital, UZG, Ghent, Belgium, Ospedale Pediatrico Bambino Gesù, OPBG, Rome, Italy, Newcastle University, UNEW, Newcastle, UK, Vall d'Hebron Institute of Oncology (VHIO) and Banc de Sang I Teixits (BST), Barcelona, Spain
AdV Infection, EBV Infection, CMV Infection, Stem Cell Transplant Complications
06/24
12/24
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting
3
482
Europe
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)
Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH
Multiple Myeloma
03/28
03/33
PEMAZA, NCT03769532 / 2017-004110-25: MRD-guided Treatment in NPM1mut AML Patients

Recruiting
2
28
Europe
Pembrolizumab, PEM, Keytruda®, Azacitidine, AZA, Vidaza®
Technische Universität Dresden, Merck Sharp & Dohme LLC
Acute Myeloid Leukemia
12/25
12/26
RELAX, NCT04330820 / 2018-003025-28: Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax

Active, not recruiting
1/2
55
Europe
Venetoclax Oral Tablet, Cytarabin
Technische Universität Dresden, AbbVie
Relapsed Adult AML, Refractory AML
10/23
08/25
NCT04230265: Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies

Recruiting
1
90
Europe
Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP), UniCAR02-T (IMP)
AvenCell Europe GmbH, PHARMALOG Institut für klinische Forschung GmbH
Acute Myeloid Leukemia (AML)
05/25
09/25
Besemer, Britta
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Hourglass Oct 2024 - Dec 2024 : Acceptance of regulatory submission in US for 2L+ multiple myeloma
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in Japan for 2L+ multiple myeloma (based on DREAMM-8 trial)
Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial)
More
Recruiting
3
357
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
05/29
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting
3
482
Europe
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)
Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH
Multiple Myeloma
03/28
03/33
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
MK-4002-001, NCT04184050 / 2019-004793-26: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002

Checkmark Data from trial for r/r multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Data from trial for r/r multiple myeloma at ASH 2022
Checkmark Data from trial for multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Data from trial for multiple myeloma at ASH 2022
Checkmark Data from trial for multiple myeloma at ASH 2021
More
Active, not recruiting
1
100
Europe, US
MK-4002, HPN217
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
06/25
11/25
DREAMM 9, NCT04091126 / 2019-003047-30: Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

Checkmark From DREAMM-9 trial for 1L transplant ineligible multiple myeloma at ASH 2021
Dec 2021 - Dec 2021: From DREAMM-9 trial for 1L transplant ineligible multiple myeloma at ASH 2021
Recruiting
1
144
Europe, Canada, US, RoW
Belantamab mafodotin, Bortezomib, Lenalidomide, Dexamethasone
GlaxoSmithKline
Multiple Myeloma
11/24
06/25
Hagen, Rudolf
NCT04611555: ICF in Cochlear Implant Users

Recruiting
N/A
100
Europe, RoW
University Hospital, Antwerp, World Hearing Centre, Hospital Universitario La Paz, Fiona Stanley Hospital, Wuerzburg University Hospital
Hearing Loss
06/22
06/22
NCT06007170: Performance of the SPIRION Laryngeal Pacemaker in BVFP Patients Without Glottal Enlargement

Recruiting
N/A
20
Europe
SPIRION Laryngeal Pacemaker System Implantation and follow-up
MED-EL Elektromedizinische Geräte GesmbH
Bilateral Vocal Cord Paralysis
12/27
12/28
NCT06007144: Performance of the SPIRION Laryngeal Pacemaker in BVFP Patients With Single-sided Glottal Enlargement

Recruiting
N/A
20
Europe
SPIRION Laryngeal Pacemaker System Implantation and follow-up
MED-EL Elektromedizinische Geräte GesmbH
Bilateral Vocal Cord Paralysis
12/27
12/28
Einsele
XPORT-MM-031, NCT05028348 / 2021-001691-41: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Hourglass Jul 2024 - Dec 2024 : H2'24 - Market entry in Malaysia in combination with bortezomib and dexamethasone for r/r MM
Jul 2024 - Dec 2024: Top-line data from XPORT-MM-031 trial in combination with pomalidomide and dexamethasone for multiple myeloma
Recruiting
3
222
Europe, US
Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral
Stichting European Myeloma Network, Karyopharm Therapeutics Inc
Multiple Myeloma
03/26
03/29
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
CARTITUDE-6, NCT05257083 / 2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Stichting European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
06/33
08/40
Frietsch, Jochen
GRAPPA, NCT05153226: GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG

Active, not recruiting
3
640
Europe
Cyclophosphamide, all brands, ATG, ATG Grafalon
DKMS gemeinnützige GmbH
Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML, MDS, MDS/MPN, CMML
06/25
12/26
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting
3
482
Europe
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)
Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH
Multiple Myeloma
03/28
03/33
Besemer
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
CARTITUDE-6, NCT05257083 / 2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Stichting European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
06/33
08/40
Rasche
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32

Download Options